Video Experimental Relacionado
Updated: Jan 14, 2026
04:41
Glucose-Stimulated Insulin Secretion via Perfusion through the Mice Vasculature with an Intact Pancreas
Published on: July 25, 2025
891
Complejo poli (bis) guanidinio (oxazolina) -insulina que ejerce la liberación de insulina de acción prolongada
Haodong Zhang1, Qian Liang2, Weinan Jiang3
1State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, China.
Journal of the American Chemical Society
|October 23, 2025
Resumen
Este estudio presenta una nueva formulación de insulina sensible a la glucosa utilizando polímeros funcionalizados. La nueva formulación mantiene con éxito los niveles normales de azúcar en la sangre durante 192 horas en minicerdos diabéticos con hipoglucemia mínima.
Área de la Ciencia:
- Ciencia de los biomateriales
- Endocrinología
- Sistemas de administración de fármacos
Sus antecedentes:
- Las formulaciones de insulina sensibles a la glucosa tienen como objetivo mejorar el manejo de la diabetes mediante la imitación de la secreción natural de insulina.
- Las formulaciones actuales se enfrentan a desafíos con la liberación incontrolada de insulina y posibles eventos hipoglucémicos.
- Las interacciones electrostáticas entre los polímeros y la insulina son clave para la liberación controlada.
Objetivo del estudio:
- Desarrollar una formulación segura y eficaz de insulina sensible a la glucosa para su administración subcutánea.
- Para abordar las limitaciones de la liberación incontrolada de insulina y la hipoglucemia en las formulaciones existentes.
- Para mejorar el índice terapéutico de administración de insulina.
Principales métodos:
- Se ha desarrollado una formulación con insulina humana recombinante unida a polímeros de bis (guanidinio) funcionalizados (polioxazolina).
- Polímeros modificados con ácido fenilborónico para la sensibilidad a la glucosa.
- Se evaluó la biocompatibilidad de la formulación y el rendimiento in vivo en minicerdos diabéticos de tipo 1.
Principales resultados:
- La formulación demostró una biocompatibilidad excepcional.
- Normoglucemia mantenida durante 192 horas en minicerdos diabéticos después de una dosis única.
- Se presenta una hipoglucemia insignificante, lo que indica una liberación controlada de insulina.
Conclusiones:
- Los polímeros funcionalizados con bis (guanidinium) refuerzan efectivamente la unión a la insulina, impidiendo su liberación incontrolada.
- Esta estrategia ofrece un enfoque prometedor para el desarrollo de formulaciones avanzadas de insulina sensibles a la glucosa.
- La formulación desarrollada muestra potencial para mejorar el tratamiento de la diabetes con una carga de administración reducida.
Videos de Conceptos Relacionados
01:24Glucagon-like Receptor Agonists
840
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
840
01:06Oral Hypoglycemic Agents: Glinides
595
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
595
01:27Insulin Formulations: Types and Delivery
648
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
648
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.2K
01:25Insulin: Biosynthesis, Chemistry, and Preparation
1.2K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.2K
01:23Dipeptidyl Peptidase 4 Inhibitors
581
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
581